Aminoglycoside toxicity in neonates: something to worry about?
Toxicity has limited the use of aminoglycosides and adult studies report high rates of both ototoxicity and nephrotoxicity. Conversely paediatric studies have shown lower rates and extended interval dosing may have reduced toxicity further. We review the animal and human evidence for aminoglycoside toxicity in neonates including mechanisms, measurement and rates of toxicity; and differences between aminoglycosides and dosing regimens. We discuss genetic susceptibility and the impact of other synergistic effects.
Paediatric Infectious Diseases Research Group, Division of Clinical Sciences, St. George's, University of London, London, UK.
Alison
A
Kent
Mark A
MA
Turner
Mike
M
Sharland
Paul T
PT
Heath
D000583:Amikacin / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity*; D000617:Aminoglycosides / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D000818:Animals; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics; D007758:Ear, Inner / Q000187:drug effects; D005839:Gentamicins / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D006801:Humans; D007231:Infant, Newborn; D007668:Kidney / Q000187:drug effects
D000617:Aminoglycosides; D000890:Anti-Infective Agents; D005839:Gentamicins; D000583:Amikacin